Valuation: Fate Therapeutics, Inc.

Market Cap 248M 223M 206M 186M 348M 23.62B 352M 2.46B 980M 12.36B 931M 911M 39.24B P/E 2026 *
-1.94x
P/E 2027 * -2x
Enterprise Value 248M 223M 206M 186M 348M 23.62B 352M 2.46B 980M 12.36B 931M 911M 39.24B EV / Sales 2026 *
43.9x
EV / Sales 2027 * 52x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
10-27 Fate Therapeutics, Inc. Presents Updated Preliminary Data For FT819 In Active Lupus Nephritis At American Society Of Nephrology Kidney Week 2026 CI
10-12 Fate Therapeutics, Inc. Announces Appointment of Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, Effective October 12, 2026 CI
09-25 Fate Therapeutics Receives $15.0 Million California Institute For Regenerative Medicine CLIN2 Grant To Support Advancement Of RECLAIM-LN CI
09-25 Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial MT
09-09 Fate Therapeutics Presents Clinical Data Of FT819 And FT839 At CCR ? West 2026 Meeting CI
08-14 Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of Ft819 for the Treatment of Lupus Nephritis CI
08-14 Fate Therapeutics Treats First Patient in Phase 2 Trial of FT819 for Lupus Nephritis MT
08-13 Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-10 Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 MT
07-09 Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate CI
07-09 Fate Therapeutics Gets US FDA Approval of Investigational New Drug Application for FT839 to Treat Autoimmune Diseases MT
07-06 Fate Therapeutics Presents Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis At ISSCR 2026 Annual Meeting CI
06-30 Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from Russell 2000 Index CI
1 day+1.69%
1 week+1.93%
Current month-10.97%
1 month-11.34%
3 months-9.05%
6 months+62.31%
Current year+114.74%
1 week 2.02
Extreme 2.015
2.14
1 month 1.75
Extreme 1.75
2.58
Current year 0.97
Extreme 0.97
3.23
1 year 0.95
Extreme 0.95
3.23
3 years 0.66
Extreme 0.66105
8.83
5 years 0.66
Extreme 0.66105
66.56
10 years 0.66
Extreme 0.66105
121.16
Manager TitleAgeSince
Chief Executive Officer 49 01/01/2025
Director of Finance/CFO 47 20/10/2025
Chief Operating Officer - 01/07/2021
Director TitleAgeSince
Chairman 78 01/12/2011
Director/Board Member 70 17/03/2014
Director/Board Member 47 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
4/8/26 Sell

Chief Executive Officer

-43,947 0.0377%
4/8/26 Sell

Compliance Officer

-38,800 0.0333%
12/6/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+1.93%+41.61%+21.97% 248M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.07%-0.10%+26.70%+55.99% 44.75B
+1.84%-3.36%+17.87%+100.14% 41.62B
+0.24%-3.77%+221.40%+918.86% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.05%-0.33%+50.65%+147.86% 38.07B
Weighted average by Cap. +2.99%-0.29%+47.09%+160.44%

Financials

2026 *2027 *
Net sales 5.65M 5.07M 4.69M 4.24M 7.93M 538M 8.02M 56.03M 22.32M 282M 21.2M 20.75M 894M 4.77M 4.28M 3.95M 3.58M 6.69M 454M 6.77M 47.27M 18.83M 238M 17.89M 17.51M 754M
Net income -129M -116M -107M -96.78M -181M -12.27B -183M -1.28B -509M -6.42B -483M -473M -20.38B -146M -131M -121M -110M -205M -13.91B -207M -1.45B -577M -7.28B -548M -536M -23.1B
Net Debt - -
Projected Income Statement - Annual - Fate Therapeutics, Inc.
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
29/10/26 US$2.105 +1.69% 747,096
27/10/26 US$2.070 +0.73% 923,556
26/10/26 US$2.055 -2.61% 1,460,286
23/10/26 US$2.110 +0.96% 1,111,188
22/10/26 US$2.090 +0.97% 867,180
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Fate Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
2.070USD
Average target price
5.744USD
Spread / Average Target
+177.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fate Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FATE Stock